Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve?

Annals of Hematology

Volumn 93, Issue 11, 2014, Pages 1951-1952

  Molica, Matteo ^a   Serrao, Alessandra ^a   Saracino, Roberta ^a   Zacheo, Irene ^a   Stingone, Christof ^a   Alimena, Giuliana ^a   Breccia, Massimo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PYRAZOLE DERIVATIVE; RUXOLITINIB;

BIOASSAY; CASE REPORT; HUMAN; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; STANDARDS; TREATMENT OUTCOME;

ENDPOINT DETERMINATION; HUMANS; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PYRAZOLES; TREATMENT OUTCOME;

EID: 84921728761     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-014-2096-y     Document Type: Letter

References (6)

1. Passamonti F (2012) Classification of myeloproliferative neoplasms and prognostic factors. Am Soc Clin Oncol Educ Book 32:419–424
2. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J et al (2009) The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 33:1199–1203
3. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V et al (2012) JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 366:787–798
4. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF et al (2013) Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 98:1865–1871
5. Kwasnicka H, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, Verstovsek S (2013) Long-term intervention effects on bone marrow morphology in myelofibrosis: patients treated with ruxolitinib and best available therapy. Haematologica 98(Suppl 1), abstract S591
6. Wilkins BS, Radia D, Woodley C, El Farhi S, Keohane C, Harrison CN (2013) Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 98:1872–1876